Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy  by Behrendt, Carolyn E. et al.
From the 1
and H
rolog
Resea
Financial d
Correspon
City
(e-ma
Received S
1083-8791
doi:10.101
54Donor and Recipient CMV Serostatus and Outcome of
Pediatric Allogeneic HSCT for Acute Leukemia in the Era
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Carolyn E. Behrendt,1 Joseph Rosenthal,2,3 Ellen Bolotin,2,3 Ryotaro Nakamura,2 John Zaia,4
Stephen J. Forman2In the era of cytomegalovirus (CMV)-preemptive therapy, it is unclear whether CMV serostatus of donor or
recipient affects outcome of allogeneic hematopoietic stem cell transplantation (HSCT) among children with
leukemia. To investigate, consecutive patients aged 0-18 who underwent primary HSCT for acute leukemia in
1997-2007 (HLA-matched sibling or unrelated donor, myeloablative conditioning, unmanipulated bone mar-
row or peripheral blood, preemptive therapy, no CMV prophylaxis) were followed retrospectively through
January 2008. Treatment failure (relapse or death) was analyzed using survival-based proportional hazards
regression. Competing risks (relapse and nonrelapse mortality, NRM) were analyzed using generalized linear
models of cumulative incidence-based proportional hazards. Excluding 4 (2.8%) patients lacking serostatus of
donor or recipient, there were 140 subjects, of whom 50 relapsed and 24 died in remission. Pretransplant
CMV seroprevalencewas 55.7% in recipients, 57.1% in donors. Thirty-five (25.0%) grafts were from seroneg-
ative donor to seronegative recipient (D2/R2). On univariate analysis, D2/R2 grafts were associated with
shorter relapse-free survival (RFS) than other grafts (median 1.06 versus 3.15 years, P\.05). Adjusted for
donor type, diagnosis, disease stage, recipient and donor age, female-to-male graft, graft source, and year,
D2/R2 graft was associated with relapse (hazards ratio 3.15, 95% confidence interval 1.46-6.76) and treat-
ment failure (2.45, 1.46-4.12) but not significantly with NRM (2.00, 0.44-9.09). In the current era, children
who undergo allogeneic HSCT for acute leukemia have reduced risk of relapse and superior RFS when
recipient and/or donor is CMV-seropositive before transplantation. However, no net improvement in RFS
would be gained from substituting seropositive unrelated for seronegative sibling donors.
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PrognosisINTRODUCTION
In the current era of effective prophylactic and pre-
emptive therapy, cytomegalovirus (CMV), once a lead-
ing infectious cause of death after hematopoietic stem
cell transplantation (HSCT), is now an infrequent
cause of early mortality. Yet donor or recipient CMV
seropositivity may still confer a survival disadvantage,
particularly when the graft is T cell depleted [1].Division of Biostatistics and Epidemiology; 2Hematology
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6/j.bbmt.2008.10.023Mechanisms proposed for an indirect adverse effect
of CMV include virally mediated immunosuppression
(resulting in increased risk of bacterial and fungal
infections) [2,3] and increased risk of acute graft-
versus-host disease (GVHD) [4,5].
In order to prevent CMV transmission from sero-
positive donor to seronegative recipient, it has been
recommended that CMV-seronegative patients re-
ceive grafts from seronegative donors whenever possi-
ble [6]. For a seropositive recipient, on the other hand,
the choice of donor is currently controversial [1,6,7].
Some studies have reported a beneficial effect of sero-
positive donor, either reduction in relapse [8,9] or re-
duction in nonrelapse mortality (NRM) [10,11],
whereas other studies have found no benefit from sero-
positive donor [1,2,12,13].
Three pediatric studies have investigated the effect
of donor and recipient CMV serostatus onHSCT out-
comes. In the first 2 studies (one of Philadelphia
chromosome-positive chronic myeloid leukemia [14],
the other of acute or chronic leukemia [15]),
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used until the final years of study enrollment. No asso-
ciation was detected between relapse or NRM and
donor or recipient serostatus [14] or seronegative do-
nor-recipient pair [15]. In the third study, preemptive
antiviral therapy was routine [16]. However, CMV
prophylaxis was also standard; in addition, the sample
was small and combined nonmalignant with malignant
cases. In that study, the primary endpoint was CMV
disease within 12 months after HSCT, but a possible
association was noted (P 5 .05) between recipient
CMV seropositivity and increased NRM.
Thus, for pediatric leukemia patients in the current
era of preemptive therapy, it remains unclear whether
CMV serostatus of donor and/or recipient affects the
outcome of allogeneic HSCT. To investigate this
question, we undertook a retrospective study among
children with acute leukemia who underwent primary
allogeneic HSCT with routine use of CMV-preemp-
tive therapy.METHODS
Sample
Consecutive patients aged 0-18 who underwent
primary, myeloablative, allogeneic HSCT were stud-
ied retrospectively with the approval of the medical
center’s institutional review board. Eligible diagnoses
were acute lymphocytic leukemia (ALL), acute
myeloid or promyelocytic leukemia (AML), and mye-
lodysplastic syndrome (MDS). Eligible donors were
HLA-matched sibling (nonsyngeneic) or unrelated in-
dividuals. Eligible grafts were unmanipulated bone
marrow or peripheral blood. Transplantations were
performed between inception of the pediatric HSCT
program in March 1997 and October 2007, and sub-
jects were followed to relapse, NRM, or last contact
through January 2008.Surveillance for Early CMV Infection
Early CMV infection refers to viremia or disease
with onset by day 100. Peripheral blood samples for
CMV culture or polymerase chain reaction (PCR)
were obtained twice weekly from day 21 through day
100. Specimens other than blood were obtained
when clinically indicated. CMV viremia was defined
as 1 positive culture, 2 consecutive positive PCR tests,
or 1 quantitative PCR with viral load $5000/mL (or
$1000/mL during high-dose corticosteroid therapy
for acute GVHD [aGVHD]). Per published guidelines
[17], CMV disease was defined as clinical symptoms
together with detection of CMV in fluid, lavage, or bi-
opsy specimen from the affected organ, except CMV
retinitis, which was diagnosed on retinal examination
by an experienced ophthalmologist.CMV-Preemptive Therapy
Preemptive therapy consisted of a week of induc-
tion therapy using either ganciclovir (5 mg/kg i.v.
twice daily) or valganciclovir (450 mg/m2 orally twice
daily), followed by 5 weeks of maintenance therapy
with these same drugs given once daily, 5 days per
week; foscarnet was used instead in 1 patient. CMV
prophylaxis was not used. Standard HSCT procedures
included acyclovir (pediatric dose 250 mg/m2 i.v. every
12 hours) from day 21 to day 125 as prophylaxis
against varicella zoster and herpes simplex viruses.
Definitions
Disease stage was defined as early (AML and ALL
in first complete remission and MDS subtype refrac-
tory anemia), intermediate (AML or ALL in second
or subsequent complete remission or in first relapse),
or advanced (AML or ALL in second or higher relapse
or primary induction failure, MDS subtype refractory
anemia with excess blasts or in transformation, or
MDS, not otherwise classified). Acute GVHD refers
to cases that were grade 2-4 per Keystone Consensus
Criteria [18].
Statistical Analysis
Patients who did not achieve remission after trans-
plantation were considered to have relapsed on day 1.
No relapse or NRM was observed after 4 years from
HSCT, by whichmilestone fewer than 20% of subjects
remained in the cohort. Therefore, 4 years was the fol-
low-up period chosen for study. Relapse-free survival
was estimated using the Kaplan-Meier method [19].
Treatment failure (relapse or NRM) was analyzed us-
ing Cox proportional hazards regression [20].
Relapse and NRM constitute competing types of
treatment failure: the occurrence of 1 type precludes
the occurrence of the other. Cumulative incidence of
competing risks was calculated and compared between
groups as described by Gray [21]. In the presence of
competing risks, the common practice in cancer stud-
ies of censoring 1 type of failure in order to model the
other has been criticized as logically flawed [22].
Therefore, relapse and NRM were modeled using
amethodology appropriate for competing risks: gener-
alized linear models (complementary log-log link
function, PROC GENMOD in SAS Version 9.1,
SAS Institute Inc., Cary, NC) of cumulative inci-
dence-based proportional hazards were constructed
using the pseudovalues approach of Klein and Ander-
sen [23,24]. As in [24], a grid of 5 time points was used
when calculating pseudovalues. Specifically, days 50,
90, 160, 240, and 540 demarcated approximately equal
numbers of treatment failures per time period. The
proportionality of hazards over time was verified
[24]. If a hazard was time dependent, a cutpoint was
chosen among the 5 grid time points. A similar
Table 1. Baseline Characteristics of Pediatric HSCT Re-
cipients (n 5 140), Overall and by CMV Serostatus of Donor/
Recipient
Overall
N 5 140 N (%)
D2/R2 Graft
N 5 35 N (%)
Other Graft
N 5 105 N (%)
Male 78 (55.7) 20 (57.1) 58 (55.2)
Diagnosis
ALL 81 (57.9) 18 (51.4) 63 (60.0)
AML 54 (38.6) 16 (45.7) 38 (36.2)
MDS 5 (3.6) 1 (2.9) 4 (3.8)
Disease stage
Early 49 (35.0) 14 (40.0) 35 (33.3)
Intermediate 81 (57.9) 19 (54.3) 62 (59.1)
Advanced 10 (7.1) 2 (5.7) 8 (7.6)
Ethnicity
Hispanic White 65 (46.4) 11 (31.4) 54 (51.4)
Non-Hispanic White 56 (40.0) 20 (57.1) 36 (34.3)
Asian 13 (9.3) 2 (5.7) 11 (10.5)
African American 6 (4.3) 2 (5.7) 4 (3.8)
Donor type
Sibling 78 (55.7) 23 (65.7) 55 (52.4)
Unrelated 62 (44.3) 12 (34.3) 50 (47.6)
Donor age
0-19 Years 74 (52.9) 23 (65.7) 51 (48.6)
20-39 Years 43 (30.7) 8 (22.9) 35 (33.3)
40-55 Years 23 (16.4) 4 (11.4) 19 (18.1)
Graft source
Bone marrow 77 (55.0) 18 (51.4) 59 (56.2)
Peripheral blood 63 (45.0) 17 (48.6) 46 (43.8)
Year of transplantation
1997-2002 69 (49.3) 18 (51.4) 51 (48.6)
2003-2007 71 (50.7) 17 (48.6) 54 (51.4)
Female-to-male graft
Yes 32 (22.9) 8 (22.9) 24 (22.9)
No 108 (77.1) 27 (77.1) 81 (77.1)
Conditioning regimen
*TBI 74 (52.9) 17 (48.6) 57 (54.3)
*TBI + Etoposide 45 (32.1) 12 (34.3) 33 (31.4)
†CTX(±other)
Busulfan + †CTX
21 (15.0) 6 (17.1) 15 (14.3)
GVHD prophylaxis
Cyclosporin +
Methotrexate(±other)
81 (57.9) 24 (68.6) 57 (54.3)
Tacrolimus(±other) 51 (36.4) 11 (31.4) 40 (38.1)
Cyclosporin ±
Mycophenolate Mofetil
8 (5.7) 0 8 (7.6)
56 Biol Blood Marrow Transplant 15:54-60, 2009C. E. Behrendt et al.approach was used to model risk of aGVHD through
day 100, for which the competing risk was treatment
failure.
Covariates
CMV serostatus of donor and of recipient were ini-
tially investigated using the 4 possible combinations of
D/R serostatus. However, when 3 of the categories
(D1/R1, D1/R2, and D2/R1) were associated
with similar hazard ratios, these categories were
combined to enhance statistical power and ease of
interpretation. Thus, CMV serostatus was defined as
D2/R2 versus other grafts. In addition to CMV
serostatus of donor and recipient, standard covariates
included in all models were diagnosis, disease stage
at transplantation, donor type, recipient and donor
age female-to-male graft, graft source, and year of
transplantation. Interaction between covariates was in-
vestigated. Selection of regimens for conditioning and
GVHD prophylaxis was at physician discretion and
varied according to donor type, disease stage, diagno-
sis, and year of transplantation. Therefore, treatment
regimens were not considered as independent covari-
ates.
Sensitivity Analysis
To assess the robustness of the association between
the D2/R2 graft and relapse, further models of re-
lapse were constructed among subjects who were alive
and relapse-free at day 90 (permitting history of early
CMV infection and aGVHD to be included as covari-
ates), among subjects with similar disease (AML or
ALL in first or second complete remission), and
among subjects who received similar conditioning
and GVHD prophylaxis.ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; MDS, myelodysplastic syndromes.
*Total body irradiation, delivered in fractionated doses in 116 of 119
cases.
†Cyclophosphamide.RESULTS
Subjects
Four (2.8% of 144) eligible patients, relapse-free at
last contact, were excluded for lack of information on
CMV serostatus of donor (D) or recipient (R). In the
study sample (n 5 140, median age 11 (range: 0-18)
years), the age distribution was bimodal, with peaks
in infancy (age 1) and adolescence (ages 12-14). Pre-
transplantCMV seroprevalencewas similar among do-
nors and recipients (57.1% and 55.7%, respectively).
Distribution of CMV serostatus in D/R pairs was
D1/R1 37.9%, D1/R2 19.3%, D2/R1 17.9%,
and D2/R2 25.0%. Concordant serostatus (D1/R1
orD2/R2) wasmore common among sibling than un-
related pairs (70.5% versus 53.2%, chi-square test, P\
.05). Table 1 presents baseline characteristics for the
sample overall and for subjects with and without the
risk factor of current interest (D2/R2 graft). Nosignificant differences were present between subjects
with D2/R2 versus other grafts.
Loss to follow-up during the 4-year study window
was 5.0% (7 of 140 subjects). Another 34 (24.3%) sub-
jects were relapse-free within the study window when
their follow-up was censored at the time of study
closure. Thus follow-up of relapse-free survivors was
median 3.22 years (minimum 90 days).
Engraftment failed to occur in 2 (1.4%) recipients
(CMV D2/R2 and D2/R1, respectively). Both pa-
tients had received bone marrow grafts from unrelated
donors over age 40 during the early years of the study.
Among recipientswhodid engraft, cumulative incidence
of aGVHD (prior to any relapse) was 39.1(64.2)% at
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Figure 1. Relapse-free survival, by donor/recipient CMV serostatus
(n 5 140). Number of subjects at baseline, year 1, year 2, and year 3
were, for D2/R2 graft, 35, 16, 8, and 6, and for other grafts, 105, 59,
44, and 33, respectively.
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median 20 days (maximum 50 days, except in an outlier
case that began on day 91). In multivariate analysis that
adjusted for all covariates, aGVHD was not associated
with D2/R2 graft (0.53, 95% CI 0.21-1.34, P 5 .18)
or with serostatus of donor or recipient.
At 100 days, cumulative incidence of CMV viremia
or disease was 12.9(63.0)%. Time to onset of early
CMV infection (n 5 18) was median 42 (range: 15 to
77) days. All but 1 CMV infection occurred in recipi-
ents seropositive before transplant; the remaining
case occurred in a seronegative recipient with a sero-
negative donor (D2/R2). All cases occurred in
relapse-free patients receiving high-dose corticoste-
roids (prednisone at least 15mg twice a day, tacrolimus
at least 1mg per day, and/or cyclosporin.50mg twice
a day) as GVHD treatment or prophylaxis.
One third of early CMV infections developed into
CMVdisease (n5 5 pneumonia, n5 1 retinitis). Infec-
tion usually resolved with treatment but infrequently
was a primary cause of death (n5 2, CMV pneumonia)
or persisted intermittently (n5 1, asymptomatic infec-
tion) until death from vancomycin-resistant entero-
coccal pneumonia and sepsis. The latter 3 deaths
occurred within 90 days after transplantations per-
formed during the first half of the study.0 1 2 3 4
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Figure 2. Cumulative incidence of relapse and nonrelapse mortality
(NRM), by donor/recipient CMV serostatus (n5 140). Cumulative inci-
dence is indicated using solid lines for relapse, dashed lines for NRM.
Gray color corresponds to D2/R2 graft, black to other grafts.Relapse and NRM
During follow-up, relapse occurred in 50 subjects
(2 of whom had persistent leukemia). NRM occurred
in another 24 subjects, 14 of whom had infection as
a primary or contributing case of death. On univariate
analysis, median relapse-free survival differed (log-
rank test, P \ .05) between recipients of D2/R2
(1.06 (95% CI 0.40-3.02) years) and other grafts
(3.15 (95% CI 1.48-upper limit not reached) years
(Figure 1). When cumulative incidences of relapse
and NRM were plotted (Figure 2), the D2/R2 graft
was associated with cumulative incidence of relapse
(Gray test [21], P 5 .012) and not of NRM.
After adjustment for standard covariates, D2/R2
graft remained a significant predictor of relapse (Table
2).The associationwithD2/R2graft did not varywith
time. No interaction was present between D2/R2
graft and other covariates, indicating that the effect of
D2/R2 graft on relapse was not limited to a particular
subgroup.
Unlike relapse, NRM was not significantly associ-
ated with D2/R2 graft in multivariate analysis (Table
2). Of note, young recipient age had opposite effects on
the 2 competing outcomes, increasing the risk of
relapse while decreasing the risk of NRM.
When relapse andNRMwere combined into a sin-
gle outcome (treatment failure), D2/R2 graft re-
mained a significant predictor in multivariate analysis
(Table 2). Female-to-male graft, whose effect did notvary over time in the model of NRM, was nevertheless
a time-dependent covariate in the model of treatment
failure, being statistically significant through the first
50 days only. During that early period, treatment fail-
ures were predominantly (7 of 12, 58.3%) NRM;
thereafter, NRM constituted a minority (17 of 62,
27.4%) of treatment failures.
Sensitivity Analysis
To determine whether the association between
D-/R- graft and relapse was influenced by early
CMV infection or aGVHD, an additional model of
Table 2. Hazards Ratios (HR) of Relapse, NRM, and Treatment Failure Among Pediatric HSCT Recipients (N5140)
Relapse NRM Treatment Failure
*HR (95% CI) P Value *HR (95% CI) P Value †HR (95% CI) P Value
CMV serostatus
D-/R- 3.15 (1.46-6.76) .003 2.00 (0.44-9.09) .37 2.45 (1.46-4.12) <.001
Other 1.00 1.00 1.00
Disease stage
Early 0.20 (0.09-0.46) <.001 0.54 (0.09-3.04) .48 0.50 (0.28-0.88) .02
Other 1.00 1.00 1.00
Recipient age
0-7 Years 4.28 (1.90-9.64) <.001 0.07 (0.01-0.68) .02 1.58 (0.94-2.67) .08
8-18 Years 1.00 1.00 1.00
Donor type, diagnosis
Unrelated, ALL 0.96 (0.39-2.40) .93 38.07 (4.82-300.8) <.001 2.51 (1.39-4.52) .002
Unrelated, AML/MDS 1.48 (0.58-3.77) .41 0.44 (0.02-8.02) .58 1.22 (0.56-2.65) .62
Sibling, any diagnosis 1.00 1.00 1.00
Female-to-male graft
Yes 0.37 (0.12-1.14) .08 18.12 (4.39-74.84) <.0001 ‡3.85 (1.20-12.34) .02
No 1.00 1.00 1.00
Donor age
40-55 Years 0.75 (0.25-2.27) .61 2.06 (0.38-11.28) .40 1.87 (0.99-3.53) .05
0-39 Years 1.00 1.00 1.00
Graft source
Bone marrow 2.14 (0.93-4.93) .07 0.29 (0.05-1.64) .16 0.79 (0.48-1.29) .35
Peripheral blood 1.00 1.00 1.00
Year of transplantation
1997-2002 1.27 (0.58-2.78) .55 1.46 (0.41-5.14) .56 1.43 (0.87-2.38) .16
2003-2007 1.00 1.00 1.00
CI indicates confidence interval; HR, hazard ratio; ALL indicates acute lymphoblastic leukemia; AML, acutemyelogenous leukemia; MDS, myelodysplastic
syndromes; CMV, cytomegalovirus; NRM, nonrelapse mortality; HSCT, hematopoietic stem cell transplantation.
*Hazards ratios for relapse and NRM are cumulative-incidence based [23].
†Hazards ratios for treatment failure are survival-based [20].
‡In the model of treatment failure, female-to-male graft is a time-dependent covariate: the hazards ratio for female-to-male graft refers to the first 50
days only.
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day 90 (n 5 115, including 36 who subsequently re-
lapsed and 15 who died in remission). Among these
day 90 survivors were 12 (10.4%) who had developed
early CMV infection and 45 (39.1%) who had devel-
oped aGVHD. Adjusted for standard covariates,
relapse after day 90 remained associated with D2/R2
graft (hazards ratio 2.65, 95% confidence interval
[CI] 1.18-5.98, P 5 .02) and was not associated with
early CMV infection or aGVHD; neither variable
altered the association between relapse and D2/R2
graft.
Further models of relapse ascertained that the as-
sociation with D2/R2 graft did not depend on the
study’s inclusion criteria. The association remained
significant when the sample was restricted to patients
with similar disease (AML or ALL in first or second
complete remission, n 5 105), among whom the haz-
ards ratio for D2/R2 graft was 12.47, 95% CI 3.67-
42.37 (P\ .0001). Likewise, the association remained
significant when the sample was restricted to patients
who received similar treatment (irradiation-based
conditioning and GVHD prophylaxis with cyclo-
sporin plus methotrexate or with a tacrolimus-based
regimen, n 5 111), among whom the hazards ratio
was 2.66, 95% CI 1.13-6.29 (P 5 .026).DISCUSSION
According to the current study, children who un-
dergo allogeneic HSCT for acute leukemia in the era
of CMV-preemptive therapy have reduced risk of
relapse and superior relapse-free survival, with no in-
crease in risk of NRM or aGVHD, when the recipient
and/or donor is seropositive for CMV prior to trans-
plant. This finding suggests that the general recom-
mendation to select seronegative donors for
seronegative recipients [6] may not be appropriate
for pediatric patients receiving nondepleted grafts in
the current era.
For a seronegative recipient with seronegative
sibling donor, the current analysis does not support re-
placing a seronegative sibling with a seropositive unre-
lated donor, even if 1 could be located without delay.
According to the multivariate model of treatment fail-
ure (Table 2), such a substitution would achieve no net
improvement in relapse-free survival, because the
reduction in risk achieved by acquiring a seropositive
donor, thus eliminating the D2/R2 graft and its
2.45-fold hazard, would be negated by the increase in
risk gained from acquiring an unrelated donor, most
clearly in patients with ALL, where unrelated donor
conferred a 2.51-fold hazard of treatment failure.
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plained or altered the current association between
relapse and D2/R2 graft, nor did the association de-
pend on study inclusion criteria. The current inci-
dence of early CMV infection (12.9 6 3.0%) was
similar to a report of 11% DNAemia among pediatric
recipients of unmanipulated grafts [25]. Consistent
with reported predictors of early CMV infection
[25-27], all but 1 current case occurred in seropositive
recipients, and at onset of infection, all current cases
were receiving high-dose corticosteroids as GVHD
treatment or prophylaxis.
Both an adequate sample of pediatric leukemia pa-
tients and routine use of CMV-preemptive therapy
without CMV prophylaxis may be essential for a study
to be able to detect benefit fromCMV seropositivity in
recipient and/or donor. The requirement for a pediat-
ric sample may arise from greater thymic regenerative
capacity [28,29] and greater potential to mount
a CMV-specific immune response [30] reported in
children relative to adults. The requirement for pre-
emptive therapy arises from the necessity to effectively
control CMV and its complications before any poten-
tial benefit of CMV immunity or subclinical reactiva-
tion can be detected. Such benefit could be blocked
by CMV prophylaxis [16]. Therefore, studies under-
taken to verify the current association between D2/
R2 serostatus and relapse will need to exclude subjects
receiving CMV prophylaxis in addition to preemptive
therapy or else employ an analysis that controls for
possible interaction between D2/R2 serostatus and
receipt of CMV prophylaxis.
The associations currently observed with D2/R2
graft await confirmation from separate pediatric sam-
ples undergoing HSCT for acute leukemia with T
cell-replete grafts and CMV-preemptive therapy but
not CMV prophylaxis. Limitations of the current
study sample include its relatively small size (insuffi-
cient for subgroup analyses, ie, by HLA-A2 antigen
status [8,13]), its origin at a single institution, and
lack of data on cytogenetics and other factors poten-
tially associated with relapse. Also, because the study
was retrospective, it was not possible to investigate
the mechanism underlying the current association
between D2/R2 graft and relapse, which likely
involves poor graft-versus-leukemia response.
In conclusion, among pediatric patients undergo-
ing HSCT for acute leukemia in the era of CMV-
preemptive therapy, we observed a reduction in relapse
with no increase inNRMwhen the recipient and/or do-
nor were CMV-seropositive before transplantation.
This finding runs counter to experience from the previ-
ous era [1]. However, with the current era has come the
possibility that the effect ofCMVserostatus on the out-
come of HSCT may have changed, a possibility sup-
ported by evidence from the current pediatric study.
If confirmed in a separate sample of children undergo-ing HSCT for acute leukemia, the finding of clinical
benefit from CMV seropositivity in donor or recipient
will be of use in the care and study of this patient pop-
ulation, informingdonor selection, identificationof pa-
tients at high risk of relapse, and design of clinical trials.ACKNOWLEDGMENTS
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